Compare · NYXH vs SYK
NYXH vs SYK
Side-by-side comparison of Nyxoah SA (NYXH) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYXH and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 964.0x NYXH ($130.1M).
- Over the past year, NYXH is down 49.8% and SYK is down 10.8% - SYK leads by 39.1 points.
- SYK has hit the wire 5 times in the past 4 weeks while NYXH has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 8 for NYXH).
- Company
- Nyxoah SA
- Stryker Corporation
- Price
- $2.98-2.93%
- $327.50-0.63%
- Market cap
- $130.1M
- $125.43B
- 1M return
- -5.85%
- -0.03%
- 1Y return
- -49.83%
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 8
- 25
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NYXH
- SEC Form S-8 filed by Nyxoah SA
- SEC Form 20-F filed by Nyxoah SA
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Publication relating to transparency notification
- Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
- Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
- Publication relating to transparency notifications
- Information on the total number of voting rights and shares
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew